Valion Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Valion Bio, Inc. (formerly Tivic Health Systems, Inc.), a Delaware corporation, on May 1, 2026. The report discloses the appointment of a new senior executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation details:
- Base Salary: $321,000 per annum for the new General Counsel.
- Annual Bonus: Eligible for up to 35% of base salary, at the Board's discretion, commencing the year following employment start.
- Equity Grant: Option to purchase 45,000 shares of common stock at fair market value on the grant date.
- Severance: Up to six months of base salary and COBRA coverage if terminated without cause or for good reason after six months of service.
Material Changes
On May 4, 2026, Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs. This represents a material change in the Company's executive leadership structure. Ms. Lackey brings over 18 years of legal and corporate experience, including prior roles at Alaunos Therapeutics, Inc., Kuur Therapeutics, Inc., and Winston & Strawn LLP.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding risks and uncertainties that could cause actual results to differ from expectations. No specific business guidance, operational outlook, or new contingencies were disclosed in this report. The employment agreement is "at-will," allowing termination by either party at any time.
Key Facts for Investor Verification
- Verify the impact of the new General Counsel's appointment on the Company's legal strategy and operational oversight.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for specific vesting schedules of the 45,000 stock options.
- Confirm the Company's current cash position to ensure it can support the new executive compensation package, as no financial statements are included in this filing.
- Monitor future filings for any changes to the Board of Directors or Compensation Committee that may influence the discretionary bonus structure.